- Home
- BRBR vs DNTH Comparison
BRBR vs DNTH Comparison
Compare BRBR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | DNTH |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.8B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BRBR | DNTH |
|---|---|---|
| Price | $16.20 | $87.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $36.63 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.0M | 753.9K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,316,600,000.00 | $2,036,000.00 |
| Revenue This Year | $6.28 | N/A |
| Revenue Next Year | $5.81 | $29.48 |
| P/E Ratio | $45.00 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $14.19 | $16.77 |
| 52 Week High | $79.57 | $96.50 |
Technical Indicators
Market Signals| Indicator | BRBR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 54.75 |
| Support Level | $16.05 | $33.94 |
| Resistance Level | $17.13 | $88.45 |
| Average True Range (ATR) | 0.74 | 3.74 |
| MACD | 0.20 | -1.19 |
| Stochastic Oscillator | 66.11 | 33.16 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.